Endocrine Abstracts

Prolactinoma (PRM) treatment is based upon dopamine agonists, cabergoline (CAB) being one of the most used in the last decade. Sensitivity to CAB varies in terms of tumour volume and PRL secretion, up to 8–15% of PRM being defined as resistant. Since it is known that increasing the dosage improves the response rate, we aimed to measure plasma CAB levels in PRM patients under this treatment in a prospective interventional study.Patients and methods: ...

Cabergoline (CAB) is a selective dopamine D2-receptor agonist with long-lasting action, highly effective in treating micro- and macroprolactinoma. However, the clinical response to cabergoline can be seen only after several months of treatment, allowing the tumor shrinkage and decrease of prolactin. Despite most prolactinomas are responsive to CAB, there are up to 8% of cases in which tumor responsivity is limited. In order to asses the sensitivity to Cab, we aimed to develop ...

Primary therapy in prolactinomas, the most frequent pituitary adenomas, consists in ergot derivatives dopamine agonists (bromocriptine or cabergoline) which lowers prolactin levels and shrink the tumour. Bromocriptine was the first drug used, but the therapeutic levels are attained after several days/weeks, therefore an acute suppression test is not possible. However, the biological response is variable and 10% of prolactinomas are resistant to medical therapy. In order to eva...